April 23rd 2024
The approval is supported by findings of the ongoing QUILT-3.032 trial, assessing nogapendekin alfa inbakicept (N-803) plus BCG in patients with BCG-unresponsive non–muscle-invasive bladder cancer.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Emulating target trials using observational evidence to inform clinical decision-making
June 2nd 2023"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Treatment Options for Non-Muscle-Invasive Bladder Cancer
May 22nd 2023Eric A. Singer, MD, MA, FACS, an expert urologic oncologist, discusses the use of Bacillus Calmette-Guerin (BCG) as a first-line therapy for non-muscle-invasive bladder cancer (NMIBC), and reviews subsequent treatment options for patients with high-risk NMIBC who are found to be unresponsive to BCG.
Dr. Daneshmand on safety of TAR-200 intravesical chemo delivery system in NMIBC
May 22nd 2023Siamak Daneshmand, MD, discusses the safety profile for TAR-200 from the phase 2b SUNRISE-1 trial, which explored the novel intravesical chemo delivery system in patients with BCG-unresponsive on–muscle-invasive bladder cancer.
Hackensack Meridian Health partners with Etta.io to enhance bladder cancer detection with AI
May 12th 2023"What was great about this partnership is we recognized that this is going to be the future of medicine at some point, and we want to be able to be a part of that cutting edge technology," says Nitin K. Yerram, MD.
The role that social determinants of health play in outcomes for patients with MIBC
May 9th 2023"Proxies for social determinants of health that we found to be associated with higher overall mortality included living in a more deprived area, as well as having Medicaid or Medicare insurance," says David Miller, MD.
Oncolytic immunotherapy CG0070 plus pembrolizumab shows promise in BCG–unresponsive NMIBC
May 3rd 2023Preliminary findings from the single-arm, phase 2 CORE-001 trial showed that the combination of the oncolytic immunotherapy cretostimogene grenadenorepvec (CG0070) and pembrolizumab (Keytruda) elicited a high complete response rate in patients with BCG–unresponsive non–muscle invasive bladder cancer.
Mitomycin gel shows promise in patients with UTUC and imperative indications for therapy
May 3rd 2023“The results of the study imply that UGN-101 is not only a renal-preserving therapy for UTUC in this comorbid population, but could potentially delay the time to dialysis or radical nephroureterectomy," says Kyle M. Rose, MD.
Intravesical chemotherapy device shows promise in muscle-invasive bladder cancer
April 14th 2023"Our preliminary clinical trial found that TAR-200 was generally safe, well tolerated, and had beneficial effects on bladder cancer outcomes in a group of patients with limited treatment options," said Mark Tyson, MD, MPH.
Expert: Work needed to validate changes in diagnostic work-up for upper tract urothelial carcinoma
April 12th 2023“I think clinicians can really take away that we have more work to be done in this space of evaluating patients with microhematuria, specifically when it comes to looking at assessments of upper tract urothelial carcinoma or renal cell carcinoma,” says Jacob Taylor, MD, MPH.